Chinese General Practice ›› 2024, Vol. 27 ›› Issue (12): 1511-1518.DOI: 10.12114/j.issn.1007-9572.2023.0452
Special Issue: 阿尔茨海默病最新文章合辑; 脑健康最新研究合辑
• Original Research • Previous Articles Next Articles
Received:
2023-09-11
Revised:
2023-11-20
Published:
2024-04-20
Online:
2024-01-23
Contact:
LIU Dan
通讯作者:
刘丹
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2023.0452
第一作者 | 国家 | 发表时间(年) | 样本量(例) | 性别(女/男) | 年龄(岁) | 音乐治疗干预特征 | 结局指标 | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
实施方式 | 干预措施 | 治疗周期(周) | 治疗时长(min) | 治疗频次(次/周) | 测评时间 | |||||||
GULLIVER[ | 澳大利亚 | 2021 | 16 | 6/9 | 80.83±9.57 | 团体 | 接受式+主动式音乐治疗 | 8 | 45~60 | 8 | 干预前、干预后 | (2) |
PITKÄNEN[ | 芬兰 | 2019 | 175 | 96/79 | 77.7±8.2 | 团体 | 接受式+主动式音乐治疗 | 52 | 45 | 2 | 干预前、干预后 | (2)(3) |
FLO[ | 挪威 | 2022 | 135 | 未提及 | 未提及 | 团体+个体 | 接受式+主动式音乐治疗 | 40 | 30 | 1 | 干预前、干预后 | (1) |
TATIANA-DANAI[ | 希腊 | 2022 | 60 | 31/29 | 75.83±8.76 | 团体+个体 | 接受式音乐治疗 | 12 | 45 | 5 | 干预前、干预后 | (2) |
KWAK[ | 美国 | 2020 | 59 | 46/13 | 88.92±5.41 | 个体 | 接受式音乐治疗 | 14 | 65 | 2 | 干预前、干预第6周、干预第14周后 | (2) |
INNES[ | 美国 | 2021 | 40 | 29/11 | 64.15±1.4 | 团体 | 接受式音乐治疗 | 12 | 12 | 7 | 干预前、干预后 | (2)(4)(3) |
GÓMEZ-GALLEGO[ | 西班牙 | 2021 | 90 | 55/35 | 80.87±6.5 | 团体 | 接受式+主动式音乐治疗 | 12 | 45 | 2 | 干预前、干预后 | (1)(2)(3) |
LIU[ | 中国 | 2021 | 50 | 0/50 | 86.75±5.1 | 团体 | 主动式音乐治疗 | 12 | 60 | 1 | 干预前、干预第6周、干预第12周后 | (2) |
CHÉOUR[ | 西班牙 | 2022 | 26 | 0/26 | 76.23±4.27 | 个体 | 接受式音乐治疗 | 16 | 60 | 3 | 干预前、干预后 | (1) |
CHEN[ | 中国 | 2020 | 43 | 32/11 | 83.00±5.03 | 团体 | 接受式+主动式音乐治疗 | 12 | 40 | 2 | 干预前、干预第6周、干预第16周后 | (1)(2)(3) |
JUNG[ | 韩国 | 2020 | 59 | 43/16 | 77.2±7.1 | 团体 | 主动式音乐疗法 | 8 | 60 | 1 | 干预前、干预后 | (1)(2)(3) |
孟爽[ | 中国 | 2019 | 84 | 46/38 | 66.4±3.9 | 团体 | 接受式音乐治疗 | 8 | 30 | 14 | 干预前、干预后 | (1)(2)(4) |
王亚军[ | 中国 | 2022 | 70 | 29/41 | 71.52±2.83 | 个体 | 接受式音乐治疗 | 8 | 未提及 | 未提及 | 干预前、干预后 | (1)(2)(3) |
肖杰屏[ | 中国 | 2018 | 50 | 30/20 | 73.89±7.52 | 团体+个体 | 接受式+主动式音乐治疗 | 16 | 40 | 14 | 干预前、干预第8周、干预第16周后 | (1)(2)(4) |
胡月青[ | 中国 | 2021 | 120 | 66/54 | 82.20±6.09 | 个体 | 接受式音乐治疗 | 4 | 30 | 7 | 干预前、干预后 | (4) |
Table 1 Basic characteristics of the included literature
第一作者 | 国家 | 发表时间(年) | 样本量(例) | 性别(女/男) | 年龄(岁) | 音乐治疗干预特征 | 结局指标 | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
实施方式 | 干预措施 | 治疗周期(周) | 治疗时长(min) | 治疗频次(次/周) | 测评时间 | |||||||
GULLIVER[ | 澳大利亚 | 2021 | 16 | 6/9 | 80.83±9.57 | 团体 | 接受式+主动式音乐治疗 | 8 | 45~60 | 8 | 干预前、干预后 | (2) |
PITKÄNEN[ | 芬兰 | 2019 | 175 | 96/79 | 77.7±8.2 | 团体 | 接受式+主动式音乐治疗 | 52 | 45 | 2 | 干预前、干预后 | (2)(3) |
FLO[ | 挪威 | 2022 | 135 | 未提及 | 未提及 | 团体+个体 | 接受式+主动式音乐治疗 | 40 | 30 | 1 | 干预前、干预后 | (1) |
TATIANA-DANAI[ | 希腊 | 2022 | 60 | 31/29 | 75.83±8.76 | 团体+个体 | 接受式音乐治疗 | 12 | 45 | 5 | 干预前、干预后 | (2) |
KWAK[ | 美国 | 2020 | 59 | 46/13 | 88.92±5.41 | 个体 | 接受式音乐治疗 | 14 | 65 | 2 | 干预前、干预第6周、干预第14周后 | (2) |
INNES[ | 美国 | 2021 | 40 | 29/11 | 64.15±1.4 | 团体 | 接受式音乐治疗 | 12 | 12 | 7 | 干预前、干预后 | (2)(4)(3) |
GÓMEZ-GALLEGO[ | 西班牙 | 2021 | 90 | 55/35 | 80.87±6.5 | 团体 | 接受式+主动式音乐治疗 | 12 | 45 | 2 | 干预前、干预后 | (1)(2)(3) |
LIU[ | 中国 | 2021 | 50 | 0/50 | 86.75±5.1 | 团体 | 主动式音乐治疗 | 12 | 60 | 1 | 干预前、干预第6周、干预第12周后 | (2) |
CHÉOUR[ | 西班牙 | 2022 | 26 | 0/26 | 76.23±4.27 | 个体 | 接受式音乐治疗 | 16 | 60 | 3 | 干预前、干预后 | (1) |
CHEN[ | 中国 | 2020 | 43 | 32/11 | 83.00±5.03 | 团体 | 接受式+主动式音乐治疗 | 12 | 40 | 2 | 干预前、干预第6周、干预第16周后 | (1)(2)(3) |
JUNG[ | 韩国 | 2020 | 59 | 43/16 | 77.2±7.1 | 团体 | 主动式音乐疗法 | 8 | 60 | 1 | 干预前、干预后 | (1)(2)(3) |
孟爽[ | 中国 | 2019 | 84 | 46/38 | 66.4±3.9 | 团体 | 接受式音乐治疗 | 8 | 30 | 14 | 干预前、干预后 | (1)(2)(4) |
王亚军[ | 中国 | 2022 | 70 | 29/41 | 71.52±2.83 | 个体 | 接受式音乐治疗 | 8 | 未提及 | 未提及 | 干预前、干预后 | (1)(2)(3) |
肖杰屏[ | 中国 | 2018 | 50 | 30/20 | 73.89±7.52 | 团体+个体 | 接受式+主动式音乐治疗 | 16 | 40 | 14 | 干预前、干预第8周、干预第16周后 | (1)(2)(4) |
胡月青[ | 中国 | 2021 | 120 | 66/54 | 82.20±6.09 | 个体 | 接受式音乐治疗 | 4 | 30 | 7 | 干预前、干预后 | (4) |
研究干预特征 | 纳入文献数量(篇) | 总例数(例) | 异质性检验结果 | MD(95%CI) | Meta分析结果 | ||
---|---|---|---|---|---|---|---|
I2(%) | P值 | Z值 | P值 | ||||
治疗周期(周) | |||||||
<12 | 3[ | 230 | 93 | <0.001 | 4.66(1.08~8.25) | 2.55 | 0.01 |
≥12 | 5[ | 210 | 96 | <0.001 | 4.17(-0.05~8.39) | 1.94 | 0.05 |
治疗时长(min/次) | |||||||
<45 | 4[ | 170 | 95 | <0.001 | 5.15(0.85~9.45) | 2.35 | 0.02 |
≥45 | 3[ | 200 | 92 | <0.001 | 2.43(-1.36~6.23) | 1.26 | 0.21 |
治疗频次(次/周) | |||||||
<3 | 4[ | 265 | 97 | <0.001 | 2.59(-2.20~7.38) | 1.06 | 0.29 |
≥3 | 3[ | 105 | 0 | 0.51 | 6.04(4.79~7.29) | 9.47 | <0.001 |
实施方式 | |||||||
个体 | 2[ | 83 | 0 | 0.97 | 6.77(5.52~8.03) | 10.61 | <0.001 |
团体 | 4[ | 272 | 91 | <0.001 | 1.74(-1.14~4.63) | 1.18 | 0.24 |
个体+团体 | 2[ | 85 | 90 | 0.002 | 7.26(2.65~11.87) | 3.09 | 0.002 |
干预措施 | |||||||
接受式音乐治疗 | 3[ | 125 | 0 | 0.88 | 6.29(5.56~7.62) | 12.55 | <0.001 |
主动式音乐治疗 | 1[ | 118 | 1.00(-0.72~2.72) | 1.14 | 0.25 | ||
接受式+主动式音乐治疗 | 4[ | 197 | 97 | <0.001 | 3.52(-1.54~8.58) | 1.36 | 0.17 |
Table 2 Subgroup analysis of the effect of music therapy on cognitive function in patients with Alzheimer's
研究干预特征 | 纳入文献数量(篇) | 总例数(例) | 异质性检验结果 | MD(95%CI) | Meta分析结果 | ||
---|---|---|---|---|---|---|---|
I2(%) | P值 | Z值 | P值 | ||||
治疗周期(周) | |||||||
<12 | 3[ | 230 | 93 | <0.001 | 4.66(1.08~8.25) | 2.55 | 0.01 |
≥12 | 5[ | 210 | 96 | <0.001 | 4.17(-0.05~8.39) | 1.94 | 0.05 |
治疗时长(min/次) | |||||||
<45 | 4[ | 170 | 95 | <0.001 | 5.15(0.85~9.45) | 2.35 | 0.02 |
≥45 | 3[ | 200 | 92 | <0.001 | 2.43(-1.36~6.23) | 1.26 | 0.21 |
治疗频次(次/周) | |||||||
<3 | 4[ | 265 | 97 | <0.001 | 2.59(-2.20~7.38) | 1.06 | 0.29 |
≥3 | 3[ | 105 | 0 | 0.51 | 6.04(4.79~7.29) | 9.47 | <0.001 |
实施方式 | |||||||
个体 | 2[ | 83 | 0 | 0.97 | 6.77(5.52~8.03) | 10.61 | <0.001 |
团体 | 4[ | 272 | 91 | <0.001 | 1.74(-1.14~4.63) | 1.18 | 0.24 |
个体+团体 | 2[ | 85 | 90 | 0.002 | 7.26(2.65~11.87) | 3.09 | 0.002 |
干预措施 | |||||||
接受式音乐治疗 | 3[ | 125 | 0 | 0.88 | 6.29(5.56~7.62) | 12.55 | <0.001 |
主动式音乐治疗 | 1[ | 118 | 1.00(-0.72~2.72) | 1.14 | 0.25 | ||
接受式+主动式音乐治疗 | 4[ | 197 | 97 | <0.001 | 3.52(-1.54~8.58) | 1.36 | 0.17 |
研究干预特征 | 纳入文献数量(篇) | 总例数(例) | 异质性检验结果 | MD(95%CI) | Meta分析结果 | ||
---|---|---|---|---|---|---|---|
I2(%) | P值 | Z值 | P值 | ||||
治疗周期(周) | |||||||
<12 | 4[ | 256 | 94 | <0.001 | -1.65(-7.99~4.70) | 0.51 | 0.61 |
≥12 | 7[ | 449 | 82 | <0.001 | -3.55(-5.96~-1.13) | 2.88 | 0.004 |
治疗时长(min/次) | |||||||
<45 | 3[ | 132 | 79 | 0.008 | -4.97(-12.12~2.18) | 1.36 | 0.17 |
≥45 | 7[ | 503 | 80 | <0.001 | -1.70(-3.98~0.59) | 1.46 | 0.15 |
治疗频次(次/周) | |||||||
<3 | 5[ | 457 | 40 | 0.16 | -2.36(-4.19~-0.54) | 2.54 | 0.01 |
≥3 | 5[ | 178 | 92 | <0.001 | -2.31(-7.30~2.68) | 0.91 | 0.36 |
实施方式 | |||||||
个体 | 2[ | 129 | 96 | <0.001 | -3.25(-8.63~2.13) | 1.18 | 0.24 |
团体 | 7[ | 506 | 73 | <0.001 | -1.48(-4.56~1.60) | 0.94 | 0.35 |
个体+团体 | 2[ | 70 | 93 | <0.001 | -5.95(-10.87~-1.04) | 2.37 | 0.02 |
干预措施 | |||||||
接受式音乐治疗 | 5[ | 239 | 91 | <0.001 | -4.05(-6.64~-1.46) | 3.07 | 0.002 |
主动式音乐治疗 | 2[ | 161 | 0 | 0.76 | -2.95(-4.82~-1.07) | 3.08 | 0.002 |
接受式+主动式音乐治疗 | 4[ | 305 | 80 | 0.002 | -1.06(-7.79~5.68) | 0.31 | 0.76 |
Table 3 Subgroup analysis of music therapy on negative emotions in AD patients
研究干预特征 | 纳入文献数量(篇) | 总例数(例) | 异质性检验结果 | MD(95%CI) | Meta分析结果 | ||
---|---|---|---|---|---|---|---|
I2(%) | P值 | Z值 | P值 | ||||
治疗周期(周) | |||||||
<12 | 4[ | 256 | 94 | <0.001 | -1.65(-7.99~4.70) | 0.51 | 0.61 |
≥12 | 7[ | 449 | 82 | <0.001 | -3.55(-5.96~-1.13) | 2.88 | 0.004 |
治疗时长(min/次) | |||||||
<45 | 3[ | 132 | 79 | 0.008 | -4.97(-12.12~2.18) | 1.36 | 0.17 |
≥45 | 7[ | 503 | 80 | <0.001 | -1.70(-3.98~0.59) | 1.46 | 0.15 |
治疗频次(次/周) | |||||||
<3 | 5[ | 457 | 40 | 0.16 | -2.36(-4.19~-0.54) | 2.54 | 0.01 |
≥3 | 5[ | 178 | 92 | <0.001 | -2.31(-7.30~2.68) | 0.91 | 0.36 |
实施方式 | |||||||
个体 | 2[ | 129 | 96 | <0.001 | -3.25(-8.63~2.13) | 1.18 | 0.24 |
团体 | 7[ | 506 | 73 | <0.001 | -1.48(-4.56~1.60) | 0.94 | 0.35 |
个体+团体 | 2[ | 70 | 93 | <0.001 | -5.95(-10.87~-1.04) | 2.37 | 0.02 |
干预措施 | |||||||
接受式音乐治疗 | 5[ | 239 | 91 | <0.001 | -4.05(-6.64~-1.46) | 3.07 | 0.002 |
主动式音乐治疗 | 2[ | 161 | 0 | 0.76 | -2.95(-4.82~-1.07) | 3.08 | 0.002 |
接受式+主动式音乐治疗 | 4[ | 305 | 80 | 0.002 | -1.06(-7.79~5.68) | 0.31 | 0.76 |
[1] |
Alzheimer's Disease International. World Alzheimer Report 2022 Life after diagnosis:Navigating treatment,care and support[EB/OL].[2022-09-21].
|
[2] |
|
[3] |
|
[4] |
|
[5] |
|
[6] |
|
[7] |
The PRISMA 2020 statement:an updated guideline for reporting systematic reviews[EB/OL].[2021-03-29].
|
[8] |
|
[9] |
|
[10] |
|
[11] |
|
[12] |
|
[13] |
|
[14] |
|
[15] |
|
[16] |
|
[17] |
|
[18] |
|
[19] |
|
[20] |
孟爽,祁欣,闻春艳. 不同类型音乐辅助治疗阿尔茨海默病患者效果对比[J]. 中国老年学杂志,2019,39(18):4510-4513. DOI:10.3969/j.issn.1005-9202.2019.18.045.
|
[21] |
王亚军,张环环,陈明明,等. 家属协同延续性护理模式联合音乐疗法对阿尔茨海默病患者生活质量的影响[J]. 中国实用神经疾病杂志,2022,25(10):1270-1274. DOI:10.12083/SYSJ.220736.
|
[22] |
肖杰屏,谢莉,梁凌云,等. 音乐疗法对阿尔茨海默病患者的睡眠质量、生活质量、认知功能及激越行为的影响[J]. 现代生物医学进展,2018,18(20):3896-3900. DOI:10.13241/j.cnki.pmb.2018.20.021.
|
[23] |
胡月青,吕继辉,王嫱,等. 音乐疗法联合强光治疗对阿尔茨海默病患者睡眠障碍的疗效观察[J]. 首都医科大学学报,2021,42(3):367-372. DOI:10.3969/j.issn.1006-7795.2021.03.005.
|
[24] |
|
[25] |
|
[26] |
|
[27] |
|
[28] |
|
[29] |
|
[30] |
|
[31] |
|
[32] |
|
[33] |
|
[1] | HAN Xiao, LI Qiyu, GE Pu, FAN Siyuan, LIU Diyue, WU Yibo, ZHANG Qingshuang. The Impact of Behavioral Lifestyle on Quality of Life in Hypertensive Patients [J]. Chinese General Practice, 2025, 28(26): 3248-3258. |
[2] | LIAO Kexin, XIAO Yisheng. Effects of the Compatibility Extract of Huangjing Pill on the Hippocampal DG Region Stem Cells in Rats with Learning and Memory Impairments [J]. Chinese General Practice, 2025, 28(24): 3019-3025. |
[3] | WU Yue, WANG Xuetong, KE Bilian. Evaluation of Vision-related Quality of Life in Myopic Macular Degeneration Patients with Low Vision and Associated Factors [J]. Chinese General Practice, 2025, 28(23): 2908-2914. |
[4] | SHI Jiarui, WANG Zili, ZHANG Xueqing, SONG Yulei, XU Guihua, BAI Yamei. The Current Status of Initial Cognitive Screening Services in Community-based Cognitive Services Centers in Nanjing [J]. Chinese General Practice, 2025, 28(22): 2784-2790. |
[5] | ZHAO Xiaoqing, GUO Tongtong, ZHANG Xinyi, LI Linhong, ZHANG Ya, JI Lihong, DONG Zhiwei, GAO Qianqian, CAI Weiqing, ZHENG Wengui, JING Qi. Construction and Validation of a Risk Prediction Model for Cognitive Impairment in Community-dwelling Older Adults [J]. Chinese General Practice, 2025, 28(22): 2776-2783. |
[6] | WEN Min, ZHOU Yongling, LIU Jingjing, JIANG Keqing, LIU Juan, ZHU Xiaodan. The Effect and Mechanism of Compensatory Cognitive Training Based on mHealth APP on Stable Schizophrenia Patients [J]. Chinese General Practice, 2025, 28(22): 2819-2825. |
[7] | MA Panpan, WANG Sijing, YOU Na, DING Dafa, LU Yibing. Efficacy and Safety of Danuglipron and Orforglipron in the Treatment of Type 2 Diabetes Mellitus: a Meta-analysis [J]. Chinese General Practice, 2025, 28(21): 2679-2685. |
[8] | ZHU Shengjie, DIAO Huaqiong, HANG Xiaoyi, SUN Wenjun. Network Meta-analysis of Different Traditional Chinese Medicine Injections for the Treatment of Posterior Circulatory Ischemic Vertigo [J]. Chinese General Practice, 2025, 28(14): 1795-1808. |
[9] | WANG Zijing, GAO Junwen, LI Cancan, YAN Huosheng, BAI Zhongliang, XIAO Jincheng, HU Zhi. Conception and Satisfaction of Integration of Medicine and Prevention from Providers' Perspective [J]. Chinese General Practice, 2025, 28(13): 1655-1660. |
[10] | LIU Caiping, ZHANG Yanhua, TANG Jianpin, WANG Chengpeng, XUE Fengfeng, WANG Huijuan, LI Chuanwei, ZHANG Guangya, LI Huafang. Efficacy and Safety of Long-acting Risperidone Microspheres in the Maintenance Treatment of Schizophrenia [J]. Chinese General Practice, 2025, 28(13): 1622-1627. |
[11] | ZHAO Zhixin, MEI Yongxia, WANG Xiaoxuan, JIANG Hu, WANG Wenna, ZHANG Zhenxiang. Cognition and Experience of Social Participation in Stroke Survivors: a Meta-synthesis Based on Qualitative Studies [J]. Chinese General Practice, 2025, 28(10): 1273-1280. |
[12] | WANG Ganhong, ZHANG Zihao, XI Meijuan, XIA Kaijian, ZHOU Yanting, CHEN Jian. Construction of an Artificial Intelligence Model and Application for an Automatic Recognition of Traditional Chinese Medicine Herbals Based on Convolutional Neural Networks [J]. Chinese General Practice, 2025, 28(09): 1128-1136. |
[13] | FAN Jianing, CHEN Jieting, WANG Ziqi, FAN Jinhe, JING Mingxia. Analysis of the Development Trajectory of Health-related Quality of Life in Middle-aged and Elderly Patients with Cardiometabolic Diseases and the Influencing Factors [J]. Chinese General Practice, 2025, 28(08): 923-932. |
[14] | ZHAO Xinrui, HUANG Li, CAO Lichun, QU Huichao, ZHANG Meilin, LIU Huan. Status and Influencing Factors of Reversible and Potentially Reversible Cognitive Frailty among the Community-dwelling Elderly [J]. Chinese General Practice, 2025, 28(07): 824-830. |
[15] | YAO Dingye, LUO Guiping, SUN Junsheng, REN Jingjing. Diagnosis and Treatment of Halitosis: a General Practice Perspective [J]. Chinese General Practice, 2025, 28(07): 900-904. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||